Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
51. |
ECCT/22/05/03 | Anti-malaria MAb in Kenyan chi Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in an Age De-Escalation, Dose-Escalation Trial and a Randomized, Placebo-Controlled, Double-Blind Trial of Children in Western Kenya |
Principal Investigator(s) 1. Titus Kwambai 2. Laura Steinhardt 3. Robert A Seder Site(s) in Kenya 1. Siaya County Referral Hospital (Siaya county) 2. Kogelo Health Center (Siaya county) |
View |
52. |
ECCT/22/03/06 | Sickle Cell Disease A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Janet Oyieko 2. Fredrick Chite Asirwa 3. Bernhards Ogutu Site(s) in Kenya 1. Kombewa Clinical Research Centre (Kisumu county) 2. Victoria Biomedical Research institute (Kisumu county) 3. International Cancer Centre (Uasin Gishu county) 4. CREATES - Strathmore University Medical Centre (Nairobi City county) |
View |
53. |
ECCT/22/03/04 | VIBRI COVID-19-001/2021 A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda). |
Principal Investigator(s) 1. Dr. Lucas Otieno Tina Site(s) in Kenya Victoria Biomedical Research Institute, |
View |
54. |
ECCT/22/02/02 | The Women TAF-FTC Benchmark Safety and Pharmacokinetics of TAF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender women |
Principal Investigator(s) 1. Dr. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD Thika |
View |
55. |
ECCT/22/01/02 | CoVPN 3008 Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern |
Principal Investigator(s) 1. Ben Madeke Andagalu Site(s) in Kenya 1. KEMRI -USAMRD-A, Kombewa Clinical Research Centre (Kisumu county) 2. KEMRI-CGHR (Kisumu county) |
View |